Psychedelic News - Psyence | United Kingdom

News and Press Releases

Psyence Group Corporate Update

Psyence Group2022-06-02T14:04:54+00:00June 2, 2022|

Psyence Group Corporate Update

Psyence Taps Another Pharma Exec To Drive Its Clinical Program

Psyence Group2022-06-06T18:30:41+00:00May 31, 2022|

Psyence Taps Another Pharma Exec To Drive Its Clinical Program TORONTO, May 31, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use [...]

Psyence and Filament Health Enter Into Exclusive Licensing Agreements For Natural Psilocybin Products

Psyence Group2022-04-19T12:28:44+00:00April 19, 2022|

Psyence and Filament Health Enter Into Exclusive Licensing Agreements For Natural Psilocybin Products The partnership leverages Psyence’s expertise in fungi cultivation and palliative care as well as Filament’s expertise in the manufacture of pharmaceutical grade [...]

12 Next

In The News

Psyence wins ISO certification from
British Standards Institute for
psilocybin production facility

Psyence Group’s functional mushroom brand
to be sold in South Africa’s
largest coffee retail chain

Psyence Group begins trading on the
OTCQB platform in New York
to satisfy investor demand

Psyence Group launches its functional
mushroom products under the
GOODMIND banner in South Africa

In this interview with Proactive Investors, Dr. Neil Maresky
talks about his appointment as
CEO of Psyence Group.

Psyence Group ‘delighted’ to reach
psilocybin product development
agreement with Jamaican government

Market For Psychedelic Drugs Expected to Reach $6.9 Billion By 2027

Psychedelic Finance chats to Psyence CEO Jody Aufrichtig

Psyence looking to be a major player
in psychedelics using their federally
licensed facilities

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

News and Press Releases

News and Press Releases

Psyence In The News

Psyence wins ISO certification from
British Standards Institute for
psilocybin production facility

Psyence Group’s functional mushroom brand
to be sold in South Africa’s
largest coffee retail chain

Psyence Group begins trading on the
OTCQB platform in New York
to satisfy investor demand

Psyence Group launches its functional
mushroom products under the
GOODMIND banner in South Africa

In this interview with Proactive Investors, Dr. Neil Maresky
talks about his appointment as
CEO of Psyence Group.

Psyence Group ‘delighted’ to reach
psilocybin product development
agreement with Jamaican government

Market For Psychedelic Drugs Expected to Reach $6.9 Billion By 2027

Psychedelic Finance chats to Psyence CEO Jody Aufrichtig

Psyence looking to be a major player
in psychedelics using their federally
licensed facilities

Jody Aufrichtig in conversation
with the CSE’s
Barrington Miller

News and Press Releases

Psyence Group Corporate Update

Psyence Taps Another Pharma Exec To Drive Its Clinical Program

Psyence and Filament Health Enter Into Exclusive Licensing Agreements For Natural Psilocybin Products

News and Press Releases

Psyence Group Corporate Update

Psyence Taps Another Pharma Exec To Drive Its Clinical Program

Psyence and Filament Health Enter Into Exclusive Licensing Agreements For Natural Psilocybin Products

Psyence In The News

Psyence wins ISO certification from British Standards Institute for psilocybin production facility

Psyence Group’s functional mushroom brand to be sold in South Africa’s largest coffee retail chain

Psyence Group begins trading on the OTCQB platform in New York to satisfy investor demand

Psyence Group launches its functional mushroom products under the GOODMIND banner in South Africa

In this interview with Proactive Investors, Dr. Neil Maresky talks about his appointment as CEO of Psyence Group.

Psyence Group ‘delighted’ to reach psilocybin product development agreement with Jamaican government

Market For Psychedelic Drugs Expected to Reach $6.9 Billion By 2027

Psychedelic Finance chats to Psyence CEO Jody Aufrichtig

Psyence looking to be a major player in psychedelics using their federally licensed facilities

Jody Aufrichtig in conversation with the CSE’s Barrington Miller

Psyence wins ISO certification from
British Standards Institute for
psilocybin production facility

Psyence Group’s functional mushroom brand
to be sold in South Africa’s
largest coffee retail chain

Psyence Group begins trading on the
OTCQB platform in New York
to satisfy investor demand

Psyence Group launches its functional
mushroom products under the
GOODMIND banner in South Africa

In this interview with Proactive Investors, Dr. Neil Maresky
talks about his appointment as
CEO of Psyence Group.

Psyence Group ‘delighted’ to reach
psilocybin product development
agreement with Jamaican government

Psyence looking to be a major player
in psychedelics using their federally
licensed facilities

Jody Aufrichtig in conversation
with the CSE’s
Barrington Miller